Mereo BioPharma Group plc (MREO)

GB — Healthcare Sector
Peers: TERN  PDSB  INZY  HOOK  DAWN  XFOR  ABOS  AMLX  EFTR  ELEV  HEPA 

Automate Your Wheel Strategy on MREO

With Tiblio's Option Bot, you can configure your own wheel strategy including MREO - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol MREO
  • Rev/Share 0.0
  • Book/Share 0.0766
  • PB 5.7697
  • Debt/Equity 0.0124
  • CurrentRatio 8.9234
  • ROIC -0.7904

 

  • MktCap 351390000.0
  • FreeCF/Share -0.0423
  • PFCF -10.5869
  • PE -7.346
  • Debt/Assets 0.0109
  • DivYield 0
  • ROE -0.6934

 

  • Rating C+
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 4
  • P/B Score 1
  • D/E Score 4

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Initiation MREO JP Morgan -- Overweight -- $7 March 27, 2025
Initiation MREO Jefferies -- Buy -- $7 Dec. 6, 2024

News

MEREO BIOPHARMA (MREO) Upgraded to Buy: What Does It Mean for the Stock?
MREO
Published: March 20, 2025 by: Zacks Investment Research
Sentiment: Positive

MEREO BIOPHARMA (MREO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Read More
image for news MEREO BIOPHARMA (MREO) Upgraded to Buy: What Does It Mean for the Stock?

About Mereo BioPharma Group plc (MREO)

  • IPO Date 2019-04-24
  • Website https://www.mereobiopharma.com
  • Industry Biotechnology
  • CEO Dr. Denise Vera Scots-Knight Ph.D.
  • Employees 36
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency. The company has a collaboration with The University of Texas MD Anderson Cancer Center to evaluate anti-TIGIT therapeutic antibody candidate, etigilimab. Mereo BioPharma Group plc was incorporated in 2015 and is based in London, the United Kingdom.